Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Apr 15;136(8):1856-62.
doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial

Affiliations
Clinical Trial

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial

Amir Goldkorn et al. Int J Cancer. .

Abstract

Circulating tumor cells (CTC) are promising biomarkers in metastatic castration resistant prostate cancer (mCRPC), and telomerase activity (TA) is a recognized cancer marker. Therefore, we hypothesized that CTC TA may be prognostic of overall survival (OS) in mCRPC. To test this, we used a novel Parylene-C slot microfilter to measure live CTC TA in S0421, a phase III SWOG-led therapeutic trial. Blood samples underwent CTC capture and TA measurement by microfilter, as well as parallel enumeration by CellSearch (Janssen/J&J). Cox regression was used to assess baseline (pre-treatment) TA versus OS, and recursive partitioning was used to explore potential prognostic subgroups and to generate Kaplan-Meier (KM) OS curves. Samples were obtained from 263 patients and generated 215 TA measures. In patients with baseline CTC count ≥5 (47% of patients), higher CTC TA was associated with hazard ratio 1.14 (p = 0.001) for OS after adjusting for other clinical covariates including CTC counts and serum PSA at study entry. Recursive partitioning identified new candidate risk groups with KM OS curve separation based on CTC counts and TA. Notably, in men with an intermediate range baseline CTC count (6-54 CTCs/7.5 ml), low versus high CTC TA was associated with median survival of 19 versus 12 months, respectively (p = 0.009). Baseline telomerase activity from CTCs live-captured on a new slot microfilter is the first CTC-derived candidate biomarker prognostic of OS in a large patient subgroup in a prospective clinical trial. CTC telomerase activity thus merits further study and validation as a step towards molecular CTC-based precision cancer management.

Keywords: biomarker; circulating tumor cells; prognosis; prostate cancer; telomerase activity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scheme of CTC telomerase activity (TA) measurment by slot microfilter. Each specimen was passed through 2 filters in series. Filter-captured cells were lysed on filter, and the lysates were analyzed for telomerase activity by qPCR-TRAP. CTC TA equaled the difference between filter 1 and filter 2 (correction for background telomerase activity signal from WBCs).
Figure 2
Figure 2
KM overall survival curves by CART nodes baseline CTC counts and TA. Low vs. high CTC TA connotes TA below or above the median, respectively. P-value for comparison between nodes 2 and 3 (low vs. high TA) = 0.009 using 1 degree of freedom chi-square.
Figure 2
Figure 2
KM overall survival curves by CART nodes baseline CTC counts and TA. Low vs. high CTC TA connotes TA below or above the median, respectively. P-value for comparison between nodes 2 and 3 (low vs. high TA) = 0.009 using 1 degree of freedom chi-square.

Similar articles

Cited by

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. Kelly WK, Halabi S, Carducci M George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–40. - PMC - PubMed
    1. Fizazi KS, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, Nathan FE, McIntosh S, Pemberton K, Moul JW. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2013;31(14):1740–48. - PubMed
    1. Makarov DV, Loeb S, Getzenberg RG, Partin AW. Biomarkers for prostate cancer. Annu. Rev. Med. 2009;60:139–51. - PubMed
    1. Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011;17:3903–12. - PMC - PubMed

Publication types

Grants and funding